A61K 40/24
Antigen-presenting cells [apc]
Official title: Antigen-presenting cells [APC]
A61K40/24 (Antigen-presenting cells [apc]) appears on 1,165 US grants and 2,397 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,165
- Published applications
- 2,397
- Assignees
- 964
- Inventors
- 3,680
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 7 | 0 |
| 1998 | 7 | 0 |
| 1999 | 10 | 0 |
| 2000 | 11 | 0 |
| 2001 | 14 | 11 |
| 2002 | 29 | 75 |
| 2003 | 24 | 84 |
| 2004 | 18 | 96 |
| 2005 | 13 | 64 |
| 2006 | 33 | 86 |
| 2007 | 17 | 57 |
| 2008 | 29 | 82 |
| 2009 | 27 | 72 |
| 2010 | 48 | 95 |
| 2011 | 43 | 79 |
| 2012 | 42 | 76 |
| 2013 | 54 | 100 |
| 2014 | 54 | 81 |
| 2015 | 55 | 98 |
| 2016 | 67 | 80 |
| 2017 | 63 | 103 |
| 2018 | 51 | 106 |
| 2019 | 39 | 114 |
| 2020 | 48 | 123 |
| 2021 | 54 | 144 |
| 2022 | 58 | 157 |
| 2023 | 69 | 143 |
| 2024 | 62 | 139 |
| 2025 | 65 | 75 |
| 2026 | 48 | 57 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Trojan circulating tumor cells8 Sep 2026US 12,728,140 B2Astrin Biosciences, Inc.
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Methods and materials for treating cancer8 Oct 2026US 2026/0306630 A1Mayo Foundation for Medical Education and Research
- Methods of sensitizing tumors to treatment with immune checkpoint inhibitors8 Oct 2026US 2026/0306658 A1University of Florida Research Foundation, Inc.
- Chimeric engulfment receptor molecules and methods of use8 Oct 2026US 2026/0308281 A1Cero Therapeutics Holdings, Inc.
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
Most cited
By later US patents
- Immunostimulatory nucleic acid molecules for activating dendritic cells265US 6,429,199 B1University of Iowa Research Foundation · 2002
- Maturation of dendritic cells with immune response modifying compounds206US 6,558,951 B13M Innovative Properties Company · 2003
- Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens124US 5,994,126 AThe Rockefeller University · 1999
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool110US 8,637,307 B2The Trustees of the University of Pennsylvania · 2014
- Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy109US 5,830,464 AFordham University · 1998